ArticleAmerican journal of preventive medicine2026
Impact of Serotype Uncertainty on Adult Pneumococcal Vaccine Options: A Value of Information Analysis.
Article in American journal of preventive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionPotential public health effects of adult pneumococcal vaccines are uncertain because of observed changes in pneumococcal serotype epidemiology. Prior analyses favored the 21-valent pneumococcal conjugate vaccine but observed that serotype changes in some populations could decrease its favorability. Value of information analysis could guide further research to clarify uncertainty.
methodsAnalyses evaluated value of information in U.S. cohorts aged 65 years, comparing adult pneumococcal vaccines. Model parameters included vaccine serotype-specific pneumococcal disease and mortality risks from U.S. data, vaccination rates from published literature, and vaccine effectiveness from clinical trials and Delphi panel estimates. Analyses estimated expected value of perfect information and expected value of partial perfect information at willingness-to-pay thresholds from $0 to $200,000 per quality-adjusted life year gained. A secondary analysis examined those aged 50-64 years. Data were collected and analyzed in 2024.
resultsIn those aged 65 years, value of information estimates were highest at the $100,000/quality-adjusted life year gained threshold and were markedly less at higher thresholds. At $100,000/quality-adjusted life year gained, population expected value of perfect information was $178.1 million; expected value of partial perfect information for pneumococcal disease mortality and disability parameters combined was $89.6 million and for vaccine effectiveness parameters was $73.8 million. The 21-valent pneumococcal conjugate vaccine serotype incidence expected value of partial perfect information was $19 million. In those aged 50-64 years, expected value of partial perfect information for vaccine effectiveness was $2.9 million and for 21-valent pneumococcal conjugate vaccine serotype incidence was $139,080.
conclusionsValue of information results were more supportive of further research on selected parameters in those aged 65 years than in those aged 50 years. However, expected value of partial perfect information values for 21-valent pneumococcal conjugate vaccine serotype incidence was substantially lower in both age groups, supporting adult 21-valent pneumococcal conjugate vaccine use regardless of serotype uncertainty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.